Effects of Psilocybin on Attentional Set-Shifting Following Chronic Unpredictable Stress in Rats (Abstract ID: 231339)

Preclinical evaluation of psilocybin and related compounds: Inhibition of cytochrome P450 isoforms

Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS

SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models

6. Open-Label Extension of Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Continued Safety and Short-Term Efficacy Signal for Drinking, Craving, and Self-Efficacy

Cytochrome P450 Inhibition by Psilocybin and Psilocin: A Combined Molecular Dynamics and Enzymatic Screening Study

Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical

Psilocybin as an alternative to conventional treatments: A systematic review

Introduction. Limitations of conventional treatments for depression and anxiety, particularly in treatment-resistant cases, have driven interest in alternative therapeutic approaches. Psilocybin, a serotonergic agonist with demonstrated effects on neuroplasticity and large-scale brain networks, has emerged as a promising therapeutic option. Materials and met...

The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes

This systematic review and meta-analysis synthesized data from 13 clinical trials (n=606) evaluating psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. Despite early enthusiasm, the pooled standardized mean difference (-0.79, 95% confidence interval: -3.98 to 2.40, p=0.63) revealed no statistically significant...

Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials

Psilocybin-assisted therapy shows promise for depression, though current evidence relies on Phase 2 trials with notable methodological limitations. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating psilocybin-assisted therapy for major or treatment-resistant depression up to February 2024. We evaluated depre...

Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey

Abstract Background and aims Psilocybin, a psychoactive compound found in fungi commonly referred to as “magic mushrooms,” is consumed for both spiritual and recreational purposes. However, psilocybin use in Puerto Rico remains understudied. This exploratory cross-sectional survey aimed to describe patterns of use, motivations for consumption, explanatory fa...

Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol

Prolonged grief disorder (PGD) affects approximately 10% of bereaved individuals and is now formally recognized in both the DSM-5-TR and ICD-11. Despite its prevalence, PGD often responds poorly to traditional therapeutic approaches. This manuscript outlines the protocol for an early-stage open-label feasibility trial investigating the use of psilocybin, a p...

Observing the mind under psychedelics: conceptual metaphors used following four once-weekly macrodoses of psilocybin

A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression

265 Self-reported rates of psilocybin use in North Florida, 2012 to present

Objectives/Goals: Mainstream interest in psilocybin (“shrooms”) has grown over the past several years as two US states have “legalized” psilocybin and clinical trials are underway for use in multiple mental health conditions. We evaluated self-reported use of psilocybin among community members in North Florida and trends in use from 2012 to the present. Meth...

361 Effect of intravenous psilocybin on mechanical hypersensitivity in a rat model of reserpine-induced chronic centralized pain

Objectives/Goals: We recently showed that a single dose of psilocybin, a serotonergic psychedelic, attenuated mechanical hypersensitivity for up to 28 days in a rat model of formalin-induced chronic centralized pain. The goal of this study is to determine whether psilocybin can alleviate chronic pain in a rat model of reserpine-induced chronic centralized pa...

26-CCC-15854-ACC TALK ABOUT A BAD TRIP!: PSILOCYBIN USE WITH PRE-EXISTING CARDIOVASCULAR DISEASE, A CASE REPORT

MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More!

Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons

Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated h...